Institution · ActivBiotics (United States)
Most cited papers from ActivBiotics (United States)
What are the most cited papers from ActivBiotics (United States)?
The most cited paper from ActivBiotics (United States) is "Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase‐2" (Ronald E. Esser, Carol Berry, Zhengming Du et al., 2005), with 123 citations. Next come "Efficacy of Superoxide Dismutase Mimetic M40403 in Attenuating Radiation-Induced Oral Mucositis in Hamsters" (86) and "Rifalazil Treats and Prevents Relapse of Clostridium difficile -Associated Diarrhea in Hamsters" (65).
Showing 32 of 32 papers. Every paper is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase‐2 Ronald E. Esser, Carol Berry, Zhengming Du et al. · British Journal of Pharmacology | 17 Jan 2005 | 123 |
| 2 | Efficacy of Superoxide Dismutase Mimetic M40403 in Attenuating Radiation-Induced Oral Mucositis in Hamsters Christopher K. Murphy, Edward G. Fey, Brynmor A. Watkins et al. · Clinical Cancer Research | Jul 2008 | 86 |
| 3 | Rifalazil Treats and Prevents Relapse of Clostridium difficile -Associated Diarrhea in Hamsters Pauline M. Anton, Michael J. O’Brien, Efi G. Kokkotou et al. · Antimicrobial Agents and Chemotherapy | 23 Sep 2004 | 65 |
| 4 | A Randomized, Double-Blind Study Comparing Single-Dose Rifalazil With Single-Dose Azithromycin for the Empirical Treatment of Nongonococcal Urethritis in Men Walter E. Stamm, Byron E. Batteiger, William M. McCormack et al. · Sexually Transmitted Diseases | 9 Feb 2007 | 54 |
| 5 | Efficacy of a Novel Rifamycin Derivative, ABI-0043, against Staphylococcus aureus in an Experimental Model of Foreign-Body Infection Andrej Trampuž, Christopher K. Murphy, David M. Rothstein et al. · Antimicrobial Agents and Chemotherapy | 15 May 2007 | 54 |
| 6 | Development potential of rifalazil David M. Rothstein, Arthur D. Hartman, Michael H. Cynamon et al. · Expert Opinion on Investigational Drugs | Feb 2003 | 46 |
| 7 | In Vitro Activity of Novel Rifamycins against Rifamycin-Resistant Staphylococcus aureus Christopher K. Murphy, Steve Mullin, Marcia S. Osburne et al. · Antimicrobial Agents and Chemotherapy | 22 Feb 2006 | 40 |
| 8 | Rifampin-Resistant RNA Polymerase Mutants of Chlamydia trachomatis Remain Susceptible to the Ansamycin Rifalazil Robert J. Suchland, Agnès Bourillon, Érick Denamur et al. · Antimicrobial Agents and Chemotherapy | 23 Feb 2005 | 39 |
| 9 | Development potential of rifalazil and other benzoxazinorifamycins David M. Rothstein, Christo I. Shalish, Christopher K. Murphy et al. · Expert Opinion on Investigational Drugs | 30 May 2006 | 39 |
| 10 | In Vitro Time-kill Activities of Rifalazil, Alone and in Combination with Vancomycin, against Logarithmic and Stationary Cultures of Staphylococcus aureus Marcia S. Osburne, David M. Rothstein, Ronnie Farquhar et al. · The Journal of Antibiotics | Feb 2006 | 28 |
| 11 | Genomics: success or failure to deliver drug targets? Ulrich A. K. Betz, Ronald Farquhar, Karl B. Ziegelbauer · Current Opinion in Chemical Biology | 29 Jun 2005 | 26 |
| 12 | Efficacy of Novel Rifamycin Derivatives against Rifamycin-Sensitive and -Resistant Staphylococcus aureus Isolates in Murine Models of Infection David M. Rothstein, Ronald Farquhar, Klari Sirokman et al. · Antimicrobial Agents and Chemotherapy | 25 Oct 2006 | 19 |
| 13 | Rifalazil and Other Benzoxazinorifamycins in the Treatment of Chlamydia‐Based Persistent Infections David M. Rothstein, John van Duzer, Andrew L. Sternlicht et al. · Archiv der Pharmazie | Oct 2007 | 17 |
| 14 | Quantifying Gastric Helicobacter pylori Infection: A Comparison of Quantitative Culture, Urease Breath Testing, and Histology Sanjeev Tummala, Sunil G. Sheth, Jeffrey D. Goldsmith et al. · Digestive Diseases and Sciences | 11 Jan 2007 | 15 |
| 15 | Effect of Food on the Pharmacokinetics of Rifalazil, a Novel Antibacterial, in Healthy Male Volunteers YX Chen, Bernard E. Cabana, Nancy M. Kivel et al. · The Journal of Clinical Pharmacology | 20 Jun 2007 | 15 |
| 16 | In Vitro Activity of Novel Rifamycins against Gram-positive Clinical Isolates Christopher K. Murphy, Elena A. Karginova, Dan Sahm et al. · The Journal of Antibiotics | Sep 2007 | 13 |
| 17 | Activities of Rifamycin Derivatives against Wild-Type and rpoB Mutants of Chlamydia trachomatis Minsheng Xia, Robert J. Suchland, Joli A. Carswell et al. · Antimicrobial Agents and Chemotherapy | 26 Aug 2005 | 12 |
| 18 | Determination of rifalazil in dog plasma by liquid–liquid extraction and LC–MS/MS: Quality assessment by incurred sample analysis Marita Larsson, Feng Han · Journal of Pharmaceutical and Biomedical Analysis | 13 Sep 2007 | 11 |
| 19 | Randomized, Double-Blind, Multicenter Safety and Efficacy Study of Rifalazil Compared with Azithromycin for Treatment of Uncomplicated Genital Chlamydia trachomatis Infection in Women William M. Geisler, Maria Luz G. Pascual, Judy S. Mathew et al. · Antimicrobial Agents and Chemotherapy | 5 May 2014 | 11 |
| 20 | Activity of Novel Benzoxazinorifamycins against Rifamycin-Resistant Streptococcus pyogenes Steve Mullin, David M. Rothstein, Christopher K. Murphy · Antimicrobial Agents and Chemotherapy | 26 Apr 2006 | 10 |
| 21 | Strategic alliance management: lessons learned from the Bayer-Millennium collaboration Karl B. Ziegelbauer, Ronald Farquhar · Drug Discovery Today | Oct 2004 | 10 |
| 22 | Rifalazil Pretreatment of Mammalian Cell Cultures Prevents Subsequent Chlamydia Infection Robert J. Suchland, Kara Brown, David M. Rothstein et al. · Antimicrobial Agents and Chemotherapy | 25 Jan 2006 | 9 |
| 23 | Rifalazil Retains Activity Against Rifampin-resistant Mutants of Chlamydia pneumoniae David M. Rothstein, Robert J. Suchland, Minsheng Xia et al. · The Journal of Antibiotics | Aug 2008 | 8 |
| 24 | Enhanced Activity of Rifalazil in Combination with Levofloxacin, Linezolid, or Mupirocin against Staphylococcus aureus In Vitro Marcia S. Osburne, Christopher K. Murphy, David M. Rothstein · The Journal of Antibiotics | May 2006 | 6 |
| 25 | Accessing the Genomes of Uncultivated Microbes for Novel Natural Products Asunción Martínez Martínez, Joern Hopke, Ian A. MacNeil et al. · Humana Press eBooks | 16 Nov 2007 | 6 |
| 26 | Determination of rifalazil, a potent antibacterial agent, in human plasma by liquid–liquid extraction and LC–MS/MS Marita Larsson, Arthur F. Michaelis, Yongdong Zhu et al. · Journal of Chromatography B | 17 Sep 2007 | 4 |
| 27 | Lack of effect of rifalazil on ethinyl estradiol pharmacokinetics in healthy postmenopausal women YX Chen, Bernard E. Cabana, Nancy M. Kivel et al. · International Journal of Clinical Pharmacology and Therapeutics | Jul 2007 | 3 |
| 28 | Efficacy of Benzoxazinorifamycins in a Mouse Model of Chlamydia pneumoniae Lung Infection Lee Ann Campbell, Cho‐Chou Kuo, Robert J. Suchland et al. · Antimicrobial Agents and Chemotherapy | 11 Mar 2008 | 3 |
| 29 | Rifalazil and Derivative Compounds Show Potent Efficacy in a Mouse Model of H. pylori Colonization David M. Rothstein, Steve Mullin, Klari Sirokman et al. · The Journal of Antibiotics | Aug 2008 | 2 |
| 30 | ChemInform Abstract: Rifalazil and Other Benzoxazinorifamycins in the Treatment of Chlamydia‐Based Persistent Infections David M. Rothstein, John van Duzer, Andrew L. Sternlicht et al. · ChemInform | 20 Dec 2007 | 0 |
| 31 | Effect of food on the pharmacokinetics of rifalazil, a novel antibacterial, in healthy male volunteers Y. Chen, Larry W. Robertson, Jolene Carlson et al. · Clinical Pharmacology & Therapeutics | Feb 2005 | 0 |
| 32 | Next-generation emergency response robots Forrest T Buzan, George P. Paul, Seth Dunten et al. · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE | 2 Sep 2004 | 0 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.